In 2019, intracerebral hemorrhage (ICH) remains the most devastating type of stroke, with a 30-day mortality rate of 40% and 60% of survivors who are dependent 1 year after ICH.1 Intracerebral hemorrhage volume is one of the main determinants of poor outcome, and the associated estimated risk of death or dependency increases of 5% for each millimeter of growth in the short-term phase.2 Up to one-third of ICHs enlarge during the first 24 hours, and the predicted probability of growth increases nonlinearly according to the ICH volume at admission, antithrombotic use, and the time window from symptom onset to imaging.3 Because of its effect on poor prognosis, hematoma expansion represents an appealing therapeutic target. Patients at higher risk of ICH expansion may represent the perfect target for a trial evaluating hemostatic agents. While early multimodal imaging has transformed the management of ischemic stroke, multimodal imaging could contribute to identify patients at risk of hematoma expansion. The spot sign has been described as one of those interesting potential biomarkers.4
Casolla B, Cordonnier C. Is Hyperselection of Patients the Right Strategy? JAMA Neurol. Published online August 19, 2019. doi:https://doi.org/10.1001/jamaneurol.2019.0213
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: